Baird Maintains Outperform on TRACON Pharma, Lowers Price Target to $7

Benzinga · 05/11/2023 10:49
Baird analyst Joel Beatty maintains TRACON Pharma (NASDAQ:TCON) with a Outperform and lowers the price target from $8 to $7.